Listenly

Why is data validation critical when using price transparency files and claims data to identify drug pricing opportunities?

Answered at 15:45 in AH118 - Chemo, Cars, & Where Health Plan Savings May be Hiding, with Brian Cotter · The Astonishing Healthcare Podcast

— questions searchable right now

Why is data validation critical when using price transparency files and claims data to identify drug pricing opportunities?

Brian emphasizes: assume all data is incorrect until proven otherwise. Every reference data set, claims data, pharmacy data, and benchmark data must be validated for accuracy and completeness. He has found that in every analysis, every reference data set was incorrect to some level, which is why building trust and credibility in data before feeding it into tools or AI systems is essential.

Brian Cotter on The Astonishing Healthcare PodcastAll answers from this podcast →
Full answer and detailsRead the whole answer, key facts and every other question from this episode

In short

Brian emphasizes: assume all data is incorrect until proven otherwise.

Brian Cotter, Founder at Bright Spot Insights · AH118 - Chemo, Cars, & Where Health Plan Savings May be Hiding, with Brian Cotter · The Astonishing Healthcare Podcast · answer at 15:45

Key takeaways

  • Brian emphasizes: assume all data is incorrect until proven otherwise.

Quote to remember

“Assume the data is incorrect until proven otherwise. You need to work through the steps to validate the data before you can start digging in and understanding what price variation you see.”

— Brian Cotter

The full answer · about 2 min

Brian emphasizes: assume all data is incorrect until proven otherwise. Every reference data set, claims data, pharmacy data, and benchmark data must be validated for accuracy and completeness. He has found that in every analysis, every reference data set was incorrect to some level, which is why building trust and credibility in data before feeding it into tools or AI systems is essential.

Key facts

  • Oxaliplatin ASP price dropped from $2,053 in 2012 to $9.40 in Q1 2026—a 99% reduction
  • One hospital listed oxaliplatin at $29,595 compared to Medicare reimbursement under $10
  • Specialty drug spend now represents 55-60% of pharmacy spend
  • Pharmacy spend represents 25-30% of total plan spend
  • 431 drugs had price drops between Q1 2025 and Q1 2026, with drops up to 99%

People, companies and topics mentioned

Bright Spot InsightsMedicareASP (Average Sales Price)J code (J9263 for oxaliplatin/Eloxatin)Oxaliplatin (Eloxatan)Specialty drugs (oncology)Price transparency dataMedical benefit

More answers from this episode

 ·  All answers from The Astonishing Healthcare Podcast →
—
—
0:00
0:00